Researchers at Johns Hopkins University have created a latest form of mebendazole, called polymorph C, which features enhanced possibility against multiple cancers. Traditionally utilized to treat parasitic infections, this edition penetrates tumors that include hard-to-treat brain cancers, more efficiently than standard mebendazole.
